Elevated Adenosine Kinase and Decreased <i>ENTPD1</i> mRNA Levels in Peripheral Blood Leukocytes of Patients with MASLD Differentiate Metabolic Dysfunction-Associated Steatohepatitis from Hepatic Steatosis. [PDF]
Kurbatova I +3 more
europepmc +1 more source
HepDecide: A Standards-Oriented, Explainable Clinical Decision Support Prototype for the Chronic Liver-Disease Spectrum-Design, Guideline-Grounded Reporting, and a Leakage-Controlled Retrospective Evaluation. [PDF]
Tokatlı N.
europepmc +1 more source
Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation. [PDF]
Still M +8 more
europepmc +1 more source
Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling. [PDF]
Gholam MF.
europepmc +1 more source
Correction to 'Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis'. [PDF]
europepmc +1 more source
Comment on "Unveiling Resmetirom: A Systematic Review and Meta-Analysis on Its Impact on Liver Function and Safety in Non-Alcoholic Steatohepatitis Treatment". [PDF]
Ruzayqat R.
europepmc +1 more source
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. [PDF]
Khan S +14 more
europepmc +1 more source
Association of Pro-Inflammatory Diets With Increased Risk of Metabolic Dysfunction-Associated Steatohepatitis: Evidence From a Prospective Cohort Study. [PDF]
Fathi S +9 more
europepmc +1 more source
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review. [PDF]
Chan WK +6 more
europepmc +1 more source

